Source comparison
CJC-1295 No DAC & Ipamorelin Mechanism Studies: Research vs Clinical Use Comparison
Peak GH Concentration 8–12 ng/mL above baseline 13–22 ng/mL above baseline 25–35 ng/mL (rodent extrapolation) Synergistic elevation likely in humans but direct trials absent Duration of Elevated GH 60–90 minutes post-injection 90–120 minutes post-injection 120
This comparison does not assign a generated winner or score.
- Peak GH Concentration
- 8–12 ng/mL above baseline
- 13–22 ng/mL above baseline
- 25–35 ng/mL (rodent extrapolation)
- Synergistic elevation likely in humans but direct trials absent
- Duration of Elevated GH
- 60–90 minutes post-injection
- 90–120 minutes post-injection
- 120–180 minutes (rodent data)
- Extended pulse width is the primary benefit of combination
- IGF-1 Elevation (24hr)
- Minimal single-dose effect
- 15–25% above baseline (rodent)
- Repeated dosing required for sustained IGF-1 changes
- Cortisol/Prolactin Impact
- No increase at therapeutic doses
- No increase measured
- Selectivity preserved in combination. Major advantage over GHRP-6
- Receptor Mechanism
- GHRH receptor agonism
- Ghrelin receptor (GHS-R1a) agonism
- Dual-pathway activation
- Independent pathways explain synergy at receptor level
- Clinical Trial Phase Reached
- Phase II (DAC version)
- Phase II (monotherapy)
- No dedicated human trials
- Combination protocols are off-label extrapolations from monotherapy data